Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00865761 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00865761 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 40 participants.
The verdict
NCT00865761, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the relative bioavailability of 3 mg Alprazolam Extended Release Tablets by Alpharma with that of 3 mg XANAX XR® Tablets by Pharmacia \& Upjohn Company following a single oral dose (1 x 3 mg extended-release tablet) in healthy adult volunteers administrated under fasting conditions.
Interventions
- DRUG Alprazolam 3 mg Extended Release Tablets, single dose
- DRUG XANAX XR® 3 mg tablets, single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-09 |
| Est. Completion | 2005-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00865761
The ClinicalTrials.gov registry entry for NCT00865761 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alprazolam 3 mg Extended Release Tablets, single dose is the first listed.
NCT00865761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00865761 about?
NCT00865761 is a clinical study titled "A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions". The purpose of this study is to compare the relative bioavailability of 3 mg Alprazolam Extended Release Tablets by Alpharma with that of 3 mg XANAX XR® Tablets by Pharmacia \& Upjohn Company following a single oral dose (1 x 3 mg extended-release tablet) in healthy adult volunteers administrated un...
What is the current status of trial NCT00865761?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2005-09. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00865761?
The interventions under investigation include: Alprazolam 3 mg Extended Release Tablets, single dose (DRUG), XANAX XR® 3 mg tablets, single dose (DRUG).
Who is sponsoring clinical trial NCT00865761?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.